期刊文献+

雷贝拉唑三联疗法短程治疗十二指肠溃疡的疗效观察

下载PDF
导出
摘要 目的观察雷贝拉唑三联疗法5 d短程治疗根除幽门螺杆菌(HP)对十二指肠溃疡(DU)的临床疗效。方法对HP阳性的40例活动期DU,给予雷贝拉唑三联药物治疗,并与奥美拉唑三联疗法对照观察溃疡的愈合率,对比两组HP根除率。结果两组HP的根除率分别为92.5%、67.5%(P<0.05),且雷贝拉唑组第1、3天疼痛消失率明显优于奥美拉唑组(P<0.01)。两组2周溃疡愈合率达95%、90%(P>0.05)。结论雷贝拉唑三联疗法5 d治疗方案根除HP优于奥美拉唑三联疗法,具有剂量小,疗程短,HP根除率高,副作用小,溃疡愈合迅速、症状消失快等优点,是目前根除HP和治疗HP阳性DU较为理想的方案。
作者 刘洪 文艺
出处 《江西医学院学报》 CAS 2006年第5期165-166,共2页 Acta Academiae Medicinae Jiangxi
  • 相关文献

参考文献4

  • 1LIND T,VANZANTEN S V,UNGE P,et al.Eradication of Helicobacter Pylori Using One-week Triple Therapies Combining Omeprazloe with Two Antimicrobials[J].Helicobacter,1996,1(3):138-144.
  • 2GOXLDARD A,LOGAN R.One Week Low-dose Triple Therapy[J].Mint.Eur J Gastroenteral Hepatol,1995,7(1):1-5.
  • 3MIWA H,OHKURA R,MURAI T,et al.Impact of Rabeprazole,a new Praton Pump Inhibitor,in Triple Therapy of Helicobacter Pylori Infection-comparison with Omeprazole and Lansoprazole[J].Aliment Pharmacol Ther,1999,13:741-746.
  • 4郑青,吴叔明,柯美云,刘晓红,刘南植,但自力,苌新明,房殿春,肖天力,萧树东.雷贝拉唑与奥美拉唑三联疗法根除幽门螺杆菌多中心、随机、双盲、平行对照研究[J].胃肠病学,2002,7(5):272-276. 被引量:62

二级参考文献16

  • 1Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus on the management of Helicobacterpylori infection. J Gastroenterol Hepatol, 1998,13: 1~12.
  • 2European Helicobacter pylori Study Group. Current European concepts in the management ofHelicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41: 8~13.
  • 3Miwa H, Ohkura R, Murai T, Sato K, NagaharaA, Hirai S, Watanabe S, Sato N. Impact of Rabeprazole, a new proton pump inhibitor, in tripletherapy of Helicobacter pylori infection-comparison with omeprazole and lansoprazole. AlimentPharmacol Ther, 1999, 13: 741~746.
  • 4Lind T, Veldhuyzen van Zanten S, Unge P, SpillerR, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C,Idstrom JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.Helicobacter, 1996, 1: 138~144.
  • 5Besancon M, Simon A, Sachs G, Shin JM. Sites ofreaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem, 1997,272: 22438~22446.
  • 6Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison[correction of Double-blind, Placebo-Controlledcomparison] of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active gastric ulcer- a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther,1998, 12: 789~795.
  • 7Hongo M, Kimpara T, Moriyama S, Ohara S, SoneS, Tamura T, Asaki S, Toyota T. Effect of rabeprazole (E3810), a novel proton pump inhib- itor, oningastric pH in healthy volunteers. Tohodu J ExpMed, 1998, 186: 43~50.
  • 8Williams MP, Pounder RE. Review article: thepharmacology of rabeprazole. Aliment PharmacolTher, 1999, 13 (Suppl 3): S3~S10.
  • 9Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T,Finnegan V, Humphries TJ. Rabeprazole versusomeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a doubleblind, multicenter, European trial. The EuropeanRabeprazole Study Group. Dig Dis Sci, 2000, 45:845 ~853.
  • 10Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in thetreatment of active duodenal ulcer: a Europeanmulticentre study. Aliment Pharmacol Ther, 1999,13: 179~186.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部